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Objective: Female-to-male transition remains a speciﬁc clinical indication for long-term testosterone
administration. There is a limited number of studies dealing with the effect of androgen treatment on
their female receptive targets (mainly breast and uterus) and the knowledge in this ﬁeld is scarce and,
sometimes, contradictory.
Materials and Methods: We performed a prospective study including 12 patients aged between 20 years
and 32 years, with a diagnosis of gender dysphoria, treated with parenteral testosterone administration
before sexual reassignment surgery.
Results: Endometrial histology revealed the presence of active endometrium in 10 cases and secretive
endometrium in two cases. Multifollicular ovaries were observed in all cases of active endometrium,
while corpus luteum was present in the two cases of secretory endometrium. Fibroids or hypertrophic
myometrium were observed in 58% of the patients. Estrogen receptor was very high (59%) in the endo-
metrial epithelial cells and low (17%) in the myometrium. Androgen receptor expression was modest in
endometrial epithelial cells (24%) and sustained in myometrium (69%). Ki67 expression is steadily present
in all uterine compartments, varying from 8% in epithelial endometrium to 2% in the myometrium.
Conclusion: Our data suggest that long-term testosterone administration to female-to-male patients
during reproductive age induces a low proliferative active endometrium, associated with some hyper-
trophic myometrial changes.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
In recent years, a number of therapeutic protocols have included
androgens as part of the traditional postmenopausal hormonal
therapy [1,2], although there are few efﬁcacy data.
Female-to-male (FtM) transition remains a speciﬁc clinical
indication for testosterone administration. There is a limited
number of studies dealing with long-term treatments and the
effect of androgens on their targets (mainly breast and uterus)
and the knowledge in this ﬁeld is scarce and, sometimes,
contradictory.s and Gynecology, Azienda
f Medicine, University of Bari
rolia).
bstetrics & Gynecology. PublishedTheoretically, after androgen treatment, the uterine changes of
postmenopausal women may be different from those occurring in
women taking long-term androgen therapy during reproductive
age [3]. A point that still needs to be adequately addressed regards
the uterine changes induced by long-term testosterone adminis-
tration during the reproductive age.
Therefore, the purpose of this study was to determine the type
of histological and steroid receptor changes in the endometrium
and myometrium of FtM transgender individuals undergoing long-
term testosterone therapy, prior to hysterectomy during the pro-
cess of sexual reassignment surgery.Materials and methods
We performed a prospective study including 12 patients aged
between 20 years and 32 years, with a diagnosis of genderby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-V) [4]. All patients were recruited at our Department of Ob-
stetrics and Gynecology between 2011 and 2013 and were eligible
for total hysterectomy with bilateral salpingo-oophorectomy dur-
ing sexual reassignment surgery.
Patients underwent colposcopy with cytologic examination, and
pelvic ultrasound in order to exclude genital tract pathologies
contraindicating hormonal treatment.
Serum concentrations of free testosterone, total testosterone,
17-b estradiol, sex hormone binding globulin (SHBG), as well as
hematocrit and Ferriman and Gallwey score, were evaluated before
treatment, after the initiation of hormonal treatment but before
surgery, and after the surgical sex reassignment procedure.
Cross hormonal therapy started preliminarily with parenteral
administration of 100 mg testosterone enanthate along a 5.8 ± 3.8-
month period every 2 weeks and was then implemented with
intramuscular administration of testosterone enanthate at a dose of
200e250 mg every 2e3 weeks [5].
Recruited patients received androgen treatment during a period
of 31.9 ± 14.3 monthsdthe time needed to obtain the permission of
the Court to proceed to hysterectomy with bilateral salpingo-
oophorectomydwhich was performed by laparoscopic approach in
all patients.
Testosterone concentrations were measured every 3 months for
the 1st year and then every 6 months in subsequent years. The goal
was to maintain serum testosterone concentration < 55 ng/dL.
A mean time lapse of 12 months of testosterone treatment was
needed for whole phenotypic masculinization. After oophorectomy
or after masculinization has been reached, interval of testosterone
administration was reduced to 3e4 weeks, maintaining the levels
of serum testosterone within half the normal masculine levels.
The modulation of testosterone administration was based on
levels of circulating androgens, the degree of satisfaction of
masculinizing changes and absence of overdose symptoms such as
hypertension and restlessness.
Follow-up consisted mainly of the following: (1) anamnestic
surveys (menstrual history before and after the initiation of treat-
ment with androgens, occurrence of amenorrhea, recurrence of
bleeding); (2) measuring the degree of androgenization (Ferri-
maneGallwey score, changes in tone of voice, appearance of alo-
pecia and seborrhea); (3) arterial blood pressure measurement; (4)
waist circumference and hip ratio; (5) evaluation of changes in
body weight (body mass index calculation); and (6) work up with
interest on the metabolic balance and hormonal changes (follicle-
stimulating hormone, luteinizing hormone, total and free testos-
terone, SHBG, 17-b estradiol, insulin, thyroid-stimulating hormone,
and erythropoietin).
Hormonal concentrations, hematocrit values, and Ferri-
maneGallwey score taken into account in the present study are
those obtained at the last evaluation just before performing the
hysterectomy.
After surgery, every uterus was embedded in 10% buffered
formalin and sent for pathological examination. The pathologist
was asked to focus on the endometrial (epithelial and stromal) and
myometrial histologic characteristics as well as to perform an
immunohistochemical study of receptors for estrogens, progester-
one, and androgens, but also for the proliferation marker Ki67.
The following immunohistochemical probes were used to study
the abovementionedmolecules: a monoclonal antibody clone 6F11
(Novocastra; Leica Biosystems, Newcastle-Upon-Tyne, UK), was
used for estrogen receptors, with 1:50 dilution, and antigenic
unmasking in citrate; a monoclonal antibody clone 1A6 (Novocas-
tra), was used for progesterone receptors, with 1:40 dilution, and
antigenic unmasking in citrate; amonoclonal antibody clone AR441(Dako, Ely, UK), was used for androgen receptors, with 1:10 dilu-
tion, antigen unmasking in EDTA; a monoclonal antibody clone
Mib-1 (Dako), was used for Ki67, with 1:25 dilution, antigen
unmasking in citrate [6,7]. The immunohistochemical evaluation
was based on the percentage of positive cells, similarly to breast
cancer evaluation of steroidal receptors.
Deﬁnitions
The description of the endometrium also included cyclical
changes, if present, as described by Noyes [8].
Endometrium was classiﬁed as inactive when tubular glands
lined with cuboidal epithelium and low nucleusecytoplasm ratio
were present, in the absence of secretory or proliferative activity,
separated by compact stroma. Active or proliferative endometrium
was deﬁned by presence of compact cellular stroma and tubular
endometrial glands lined by column epithelium, with some of the
glands showing pseudostratiﬁcation and occasional mitosis.
The histological deﬁnition of ovary micropolycystic-like was
made in the presence of numerous cystic follicles with a diameter
between 5 mm and 10 mm, delimited by the granulosa cells and
below a thickened ovarian cortex, associated with stromal
hyperplasia.
Statistical analysis
The data on continuous variables with normal distributionwere
presented as mean ± SD, and compared between study groups
using Student t test. Categorical data were assessed by Chi-square.
A two-sided p value < 0.05 was considered signiﬁcant. Statistical
analysis was done using SPSS version 20 (SPSS Inc., Chicago, IL,
USA).
Results
Amenorrhea occurred 8e12months after starting of the therapy
and had a mean duration of 21.8 ± 8.7 months before the
hysterectomy.
Free testosterone and total testosterone concentrations pro-
gressively increased from basal value, reaching a peak at 6 months
(p < 0.001) after testosterone administration. Concentrations of 17-
b estradiol were reduced after testosterone administration due to
inhibition of folliculogenesis, reaching postmenopausal concen-
trations at 6 months after initiation of androgen therapy
(116.5 ± 62.3 pg/mL vs. 51.6 ± 18.6 pg/mL, respectively). Basal he-
matocrit values were signiﬁcantly lower than those after 6 months
of androgen treatment as well after year of therapy (39.9 ± 2.3 vs.
43.7 ± 2.8 vs. 44.6 ± 2.2, respectively; p ¼ 0.01 for all comparisons).
FerrimaneGallwey score progressively increased from pretreat-
ment value until 1 year after surgery (4.5 ± 3.7 vs. 9.9 ± 4.2 vs.
14.2 ± 4.4 vs. 16.6 ± 8.65 vs. 17.3 ± 8.96, respectively; p < 0.001 for
all comparisons). Remarkably, FerrimaneGallwey score increased
from 4.5 ± 3.7 before treatment to 16.6 ± 8.65 soon after the sur-
gery. As a result of the direct inhibition exercised by androgens on
its synthesis in the liver, SHBG concentrations underwent a slight
but signiﬁcant decrease (43.8 ± 4.6 vs. 21.9 ± 5.6; p ¼ 0.001;
Table 1).
Table 2 summarizes the results of the histological examinations
of uterus and ovaries removed obtained from the 12 patients after
surgery. Endometrial histology revealed the presence of active
endometrium in 10 cases and secretive endometrium in two cases.
Multifollicular ovaries were observed in all cases of active endo-
metrium, while corpus luteum was present in the two cases of
secretory endometrium. Fibroids or hypertrophic myometrium has
been observed in 58% (7/12) of the patients.
Table 1
Serum concentrations of total testosterone, free testosterone, 17-b estradiol, sex hormone binding globulin, as well as hematocrit and FerrimaneGallwey score values.
Before therapy After 6 mo of therapy After 12 mo of therapy 6 mo after surgery 12 mo after surgery p
Total testosterone (ng/mL) 0.6 ± 0.18 7.7 ± 2.3 6.6 ± 2.02 4.7 ± 2.4 7.8 ± 3.62 < 0.001
Free testosterone (ng/dL) 2.06 ± 0.8 28.4 ± 13.6 20.7 ± 7.9 15.5 ± 8.9 16.9 ± 7.5 < 0.001
Hematocrit (%) 39.9 ± 2.3 43.7 ± 2.8 44.6 ± 2.2 43.5 ± 1.6 44.3 ± 1.3 0.01
FerrimaneGallwey score 4.5 ± 3.7 9.9 ± 4.2 14.2 ± 4.4 16.6 ± 8.65 17.3 ± 8.96 < 0.001
17-b estradiol (pg/mL) 116.5 ± 62.0 80.9 ± 35.0 96.2 ± 38.7 17.6 ± 7.6 51.6 ± 18.6 0.22
SHBG (nM) 43.8 ± 4.6 21.9 ± 5.6 20.9 ± 8.1 24.8 ± 9.2 20.7 ± 6.2 0.001
Data are presented as mean ± SD.
SHBG ¼ sex hormone binding globulin.
Table 2
Results of the pathologic examination of endometrium, myometrium, and ovaries in
the 12 female-to-male patients.
Patient no. Age (y) Endometrium Myometrium Ovary
1 26 Secretive Fibrosis Corpus luteum
2 37 Active Normal Multifollicular
3 22 Active Fibrosis Multifollicular
4 26 Active Fibrosis Multifollicular
5 37 Active Normal Multifollicular
6 20 Active Normal Multifollicular
7 31 Active Fibrosis Multifollicular
8 34 Active Fibrosis Multifollicular
9 31 Secretive Hypertrophy Corpus luteum
10 33 Active Normal Multifollicular
11 20 Active; squamous
metaplasia
Normal Multifollicular
12 20 Active Hypertrophy Multifollicular
Table 3
Intensity of expression of hormonal receptors and Ki67 receptor.
ER PR AR Ki67
Endometrium Epithelium 54% 59% 24% 8%
Stroma 40% 40% 39% 5%
Myometrium 17% 68% 69% 2%
Data are presented as mean value.
AR ¼ androgen receptor; ER ¼ estrogen receptor; PR ¼ progesterone receptor.
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the endometrial epithelial cells, a sustained mean expression of
estrogen receptors (54%) and progesterone receptors (59%), while
the intensity of androgen receptors expression was modest (24%)
and ki67 (8%) expression very low. In the stroma, the mean
expression of estrogen and progesterone receptors was lower if
compared to the epithelium (40%), while that of androgen receptors
was higher, reaching a mean value of 39%. Lastly, myometrium had
the lowest expression of estrogen receptors (17%), but the highest
expression of progesterone (68%) and androgen receptors (69%).
Figure 1 shows the different expression of the androgen receptors
in the endometrium (epithelium and stroma) and themyometrium.
Ki67 expression was constantly low in all uterine compartments,
declining from 8% in endometrial epithelium to 2% in myometrium
(Table 3), as shown in Figure 2.Figure 1. Androgen receptor expression in the endometrium (epitheliumþ,
stroma þþ) and myometrium (þþþ) magniﬁcation (40).Discussion
The long-term effect of testosterone on human endometrium is
a subject for debate [9]. Randomized controlled trials have been
conducted and suggest that in women with surgical and natural
menopause, testosterone alone [10] or in combination with estra-
diol [11e13] has a positive impact on sexual function and is well
tolerated [9,14].
In vitro studies have suggested that high dose androgen treat-
ment could induce endometrial atrophy, through an inhibitory ef-
fect on cells proliferation, as observed with an administration of
intramuscular injection of 100 mg Testoviron Depot/10 days for at
least 1 year [15].
Androgen receptor expression in postmenopausal women versus.
women in reproductive age undergoing androgen treatment
Results of clinical studies onmenopausal women have indirectly
conﬁrmed those ﬁndings, since androgens administered in associ-
ation with estrogen apparently blunt the development of hyper-
plasia [16,17]. Moreover, adding the testosterone to treatment withFigure 2. Expression of Ki67 proliferative marker magniﬁcation (40).
Figure 3. Endometrial and myometrial expression of estrogen receptors magniﬁcation
(40).
Figure 4. Immunohistochemical study of the expression of progesterone receptors in
the endometrium layers and the myometrium magniﬁcation (40).
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as evidenced by the absence of histological changes [18].
Therefore, in postmenopausal women, a 3-month treatment
with undecanoate testosterone does not induce an increase in
endometrial proliferation but, if associated to estrogen, induces a
modest antagonistic effect on estrogen-induced proliferation [19].
The absence of stimulatory effect of testosterone on endome-
trium is moreover conﬁrmed by various experimental studies in
rodents in vivo and cell cultures in vitro [15,20].
Nevertheless, many of the aforementioned studies have been
performed in postmenopausal women, in which testosterone
administration occurred along with estrogen or estrogen/progestin
association, and usually for a short period of time [17,21,22].
By contrast, recent studies have found that long-term testos-
terone administration can induce a proliferative effect on the
endometrium in young women during reproductive age, as a
consequence of aromatization of androgens into estrogens. Fut-
terweit and Deligdisch [23] studied 19 transsexual FtM individuals
undergoing long-term treatment with a low dose of testosterone
enanthate (parenteral 400 mg every 3e4 weeks) conﬁrming the
possibility of an endometrial stimulatory effect of testosterone
administered during reproductive age. In that study, 63.2% of FtM
had a proliferative endometrium,18% had an endometrial glandular
cystic mild degree hyperplasia, and 36.8% had an inactive endo-
metrium [23], suggesting an aromatization of testosterone
executed by an endometrial aromatase.
The relationship between androgen administration and endometrial
biology in reproductive age
However, normal human endometrium is not able to aromatize
androgens to estrogen [24,25], since aromatase is not expressed in
physiological conditions by epithelial and stromal endometrial cells
[26,27], but only by cancerous endometrial cells [20]. In order to
better understand the relationship between androgen administra-
tion and endometrial biology during reproductive age, we exam-
ined uterine histological patterns, receptor status, and Ki67 in
endometrial epithelium and stroma, and myometrium, after hys-
terectomy performed during sex reassignment surgery in young
women who desire FtM reassignment.
Histologically, we have found a high rate of active endometrium,
sometimes evolving in secretory patterns, without cases of atrophic
endometrial involution.
Our ﬁndings suggest that high dose of testosterone adminis-
tered for a long period of time in young women does not induce an
endometrial atrophy, but could be associated with a persistent
although modest proliferative activity, according to the presence of
multiple follicular cysts in both ovaries resembling, from a func-
tional point of view, the picture of polycystic ovaries. This is
conﬁrmed in the literature through the association of serum
testosterone levels and polycystic ovaries according to antral folli-
cle count and ovarian volume in reproductive-aged women [28].
By contrast, the ﬁnding of sporadic secretory endometrium,
observed in 16.6% of the cases, in the presence of corpus luteum
during prolonged androgen treatment, is in agreement with a
minimal proliferative activity [29] and the unexpected high level of
expression of estrogen and progesterone receptors (Figures 3 and 4).
Androgen receptors' endometrial pattern of expression
Androgen receptors have cyclical expression patterns in human
endometrium and are considered to have an important role in fe-
male reproductive function [30]. Estrogens induce an upregulation
of mRNA and protein expression of androgen receptors while
progesterone downregulates this expression [31], according toincreased androgen receptor expression induced by progesterone
antagonists in the rhesus macaque and human endometrium [32].
Lastly, androgen administration increases the expression of
androgen receptors in endometrial adenocarcinoma cells [33].
As for the site and intensity of expression of androgen receptors
in various uterine compartments, their expression, evaluated by
immunohistochemical techniques appears more intense in endo-
metrial stromal and myometrial cells than in the endometrial
epithelial compartment [34] (Figure 1).
These ﬁndings may suggest an active role of androgens in
myometrial hypertrophy, as seen in the present study.
Moreover, in order to better understand the activity status of the
endometrium in FtM transgender during androgen treatment, we
have studied the level of Ki67 expression, as a marker of mitotic
activity.
A previous study showed that Ki67 has higher expression in
endometrial epithelium during the proliferative phase, but is ab-
sent during the secretive phase [35]. In postmenopausal women
treated with estrogen/progestin associated with testosterone, the
expression of Ki67 appears to be downregulated, if compared with
its expression in women treated with estrogen alone. By contrast,
treatment of postmenopausal women with the testosterone alone
G. Loverro et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 686e691690does not induce any changes in Ki67 endometrial expression in the
endometrial epithelium and stroma [19].
In our experience, Ki67 expression was very low in all endo-
metrial compartments (Figure 2), suggesting that the high inci-
dence of active proliferative-like endometrium is related to the low
but prolonged estrogen levels produced by multiple small ovarian
follicles.
Androgen receptor expression in the myometrial compartment
As concerning myometrial compartment, the high incidence of
ﬁbroids, myometrial hypertrophy and ﬁbrosis in FtM could be
strictly related to an intense androgen receptor expression after
prolonged testosterone administration. Recent experimental data
suggest that testosterone administration is associated with an in-
crease of satellite cells and myometrial cell hypertrophy. Indeed,
testosterone upregulates expression of follistatin and down-
regulates the expression of genes involved in transforming growth
factor-b signaling activity [36].
Ovarian ﬁndings related with androgen administration in women in
reproductive age
Lastly the ﬁndings of enlarged multifollicular ovaries, appear as
a consequence of direct or indirect effect of androgen on prolifer-
ation and growth of stromal ovarian cells inducing an increased
ovarian volume and ﬁbrous collagen content [37]. The multi-
follicular morphologic changes of ovaries due to direct effect of
androgen has been observed in an animal study in which exoge-
nous supplementation with androgens directly led to polycystic
ovaries and reduced menstrual cycles [38]. In addition, multi-
follicular morphological changes during prolonged testosterone
administration in genetically normal women could be attributed to
increased stimuli of growth factors exerted by androgens [39].
Conclusions
A large body of literature suggests an atrophic effect of long-
term androgen therapy in FtM individuals treated with testos-
terone. Our data provide evidence that testosterone administration
produces active endometrial and myometrial changes in women of
reproductive age undergoing androgen therapy during the course
of the process leading to sex reassignment surgery. This can be the
result of the association of ovarian changes, responsible for a
continuous, albeit at low concentration, estrogen production,
leading to androgen upregulation in the myometrial expression of
androgen receptors. The correlation between long-term androgen
administration and uterine histological and receptor changes is
scarce, and more studies are needed in order to establish the effect
of such therapy on uterine tissues. This is extremely important in
those patients requiring cross-sex hormone therapy for gender
dysphoria without sex reassignment surgery, who may deserve
surveillance due to the risk of endometrial degenerative changes
due the apparent proliferative activity induced by androgen
therapy.
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